The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01
- Author:
Young Zoon KIM
1
;
Chae Yong KIM
;
Chan Woo WEE
;
Tae Hoon ROH
;
Je Beom HONG
;
Hyuk Jin OH
;
Seok Gu KANG
;
Shin Hyuk KANG
;
Doo Sik KONG
;
Sung Hwan KIM
;
Se Hyuk KIM
;
Se Hoon KIM
;
Yu Jung KIM
;
Eui Hyun KIM
;
In Ah KIM
;
Ho Sung KIM
;
Jae Sung PARK
;
Hyun Jin PARK
;
Sang Woo SONG
;
Kyoung Su SUNG
;
Seung Ho YANG
;
Wan Soo YOON
;
Hong In YOON
;
Jihae LEE
;
Soon Tae LEE
;
Sea Won LEE
;
Youn Soo LEE
;
Jaejoon LIM
;
Jong Hee CHANG
;
Tae Young JUNG
;
Hye Lim JUNG
;
Jae Ho CHO
;
Seung Hong CHOI
;
Hyoung Soo CHOI
;
Do Hoon LIM
;
Dong Sup CHUNG
;
Author Information
- Publication Type:Original Article
- Keywords: Korean Society for Neuro-Oncology; Guideline; Grade II Gliomas; Practice
- MeSH: Adult; Astrocytoma; Brain; Central Nervous System; Drug Therapy; Drug Therapy, Combination; Follow-Up Studies; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Korea; Oligodendroglioma; Radiotherapy; World Health Organization
- From:Brain Tumor Research and Treatment 2019;7(2):74-84
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults. RESULTS: Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group. CONCLUSION: The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients.
